Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Bioatla Inc

Healthcare US BCAB

3.33USD
-0.16(4.58%)

Last update at 2026-06-05T20:00:00Z

Day Range

3.303.59
LowHigh

52 Week Range

3.9271.50
LowHigh

Fundamentals

  • Previous Close 3.49
  • Market Cap9.35M
  • Volume112431
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-58.33200M
  • Revenue TTM2.00M
  • Revenue Per Share TTM1.70
  • Gross Profit TTM -41.07300M
  • Diluted EPS TTM-50.5

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -59.60700M -69.77600M -123.46200M -106.48200M -95.40200M
Minority interest - - - - 0.00000M
Net income -59.60700M -69.77600M -123.46200M -105.28300M -95.40600M
Selling general administrative 17.73M 21.85M 25.96M 28.79M 38.42M
Selling and marketing expenses - - 1.22M - -
Gross profit 2.00M 10.07M -1.22100M - 0.25M
Reconciled depreciation 0.37M 0.93M 1.15M 1.20M 1.33M
Ebit -59.30500M -73.94300M -123.46200M -108.14000M -96.44000M
Ebitda -58.93200M -73.01800M -122.24100M -106.48200M -94.75900M
Depreciation and amortization 0.37M 0.93M 1.22M 1.66M 1.68M
Non operating income net other - - - 1.66M -
Operating income -59.30500M -73.94300M -129.68700M -108.14000M -96.44000M
Other operating expenses 61.30M 84.94M 129.69M 108.14M 96.69M
Interest expense - - - -1.65800M 0.00300M
Tax provision - - - - -
Interest income 0.84M 3.37M 5.72M 1.65M 0.35M
Net interest income 0.84M 3.37M 5.72M 1.65M 0.35M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - -1.19900M 0.00400M
Total revenue 2.00M 11.00M 0.00000M 0.00000M 0.25M
Total operating expenses 61.30M 84.02M 128.47M 108.14M 96.69M
Cost of revenue - 0.93M 1.22M - -
Total other income expense net -0.30200M 4.17M 6.22M 1.66M 1.04M
Discontinued operations - - - - -
Net income from continuing ops -59.60700M -69.77600M -124.08000M -106.48200M -95.40200M
Net income applicable to common shares - - - -106.48200M -95.40200M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 13.83M 52.42M 119.66M 225.74M 254.42M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.90M 2.19M 4.93M 0.54M 0.50M
Total liab 50.02M 38.16M 48.99M 45.40M 43.60M
Total stockholder equity -36.18900M 14.27M 70.67M 180.34M 210.82M
Deferred long term liab - - - - -
Other current liab 12.30M 11.80M 22.90M 17.38M 17.25M
Common stock 0.00600M 0.00600M 0.00500M 0.00500M 0.00400M
Capital stock 0.00600M 0.00600M 0.00500M 0.00500M 0.00400M
Retained earnings -545.64600M -486.03900M -416.26300M -292.80100M -186.31900M
Other liab - - - 19.81M 19.81M
Good will - - - - -
Other assets - - 0.00000M 0.15M 0.15M
Cash 7.12M 49.05M 111.47M 215.51M 244.98M
Cash and equivalents - - - - -
Total current liabilities 21.92M 14.54M 28.34M 23.13M 19.81M
Current deferred revenue - - - - -
Net debt -0.91800M -48.21000M -109.01100M -211.52600M -239.60800M
Short term debt 1.43M 0.84M 1.62M 1.52M 1.39M
Short long term debt - - - - -
Short long term debt total 6.20M 0.84M 2.46M 3.98M 5.37M
Other stockholder equity 509.45M 500.30M 486.93M 473.13M 397.14M
Property plant equipment - - - 2.73M 6.98M
Total current assets 8.01M 51.23M 116.41M 220.43M 247.29M
Long term investments - - - - -
Net tangible assets - - - 180.34M 210.82M
Short term investments - - - - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 8.19M 1.90M 3.82M 4.23M 1.18M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 0.00000M - -
Additional paid in capital - - - - -
Common stock total equity - - - 0.00500M 0.00400M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -292.80100M -186.31900M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.16M - 0.15M 0.15M 0.15M
Deferred long term asset charges - - - - -
Non current assets total 5.82M 1.19M 3.25M 5.30M 7.13M
Capital lease obligations 6.20M 0.84M 2.46M 3.98M 5.37M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00000M -0.12100M -0.26500M -0.92400M
Change to liabilities - - - 3.41M 7.99M
Total cashflows from investing activities - - -0.09800M -0.26500M -0.92400M
Net borrowings 7.12M 0.00000M - - -
Total cash from financing activities 6.28M 9.51M 0.08M 61.21M 69.51M
Change to operating activities - - - -3.12400M -0.56800M
Net income -59.60700M -69.77600M -123.46200M -106.48200M -95.40200M
Change in cash -41.92800M -62.42500M -104.03600M -29.47200M 6.37M
Begin period cash flow 49.05M 111.47M 215.51M 244.98M 238.60M
End period cash flow 7.12M 49.05M 111.47M 215.51M 244.98M
Total cash from operating activities -48.20400M -71.93600M -104.01500M -90.42000M -62.21400M
Issuance of capital stock 0.00000M 9.21M 0.00000M 61.68M 70.99M
Depreciation 0.37M 0.93M 1.22M 1.20M 1.33M
Other cashflows from investing activities - - - 0.00300M -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 0.10M 0.34M -0.00026M 0.29M 0.29M
Other cashflows from financing activities -0.94900M 0.30M -0.25900M -0.75800M -1.48200M
Change to netincome - - - 14.58M 24.43M
Capital expenditures 0.00000M 0.00000M 0.10M 0.27M 0.92M
Change receivables - - - - 0.00300M
Cash flows other operating - - - -3.12400M -0.56800M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -29.47200M 6.37M
Change in working capital 4.28M -11.19900M 4.68M 0.29M 7.42M
Stock based compensation 5.43M 8.92M 13.54M 14.56M 25.12M
Other non cash items 1.32M -0.80700M 0.00200M 0.01M 0.00300M
Free cash flow -48.20400M -71.93600M -104.11300M -90.68800M -63.13800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BCAB
Bioatla Inc		 -0.16 4.58% 3.33 - - 4.67 2.68 4.25 0.31
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Bioatla Inc

11085 Torreyana Road, San Diego, CA, United States, 92121

Key Executives

Name Title Year Born
Dr. Jay M. Short Ph.D. Co-Founder, CEO & Chairman 1958
Mr. Scott Andrew Smith Pres & Director 1962
Mr. Richard A. Waldron Chief Financial Officer 1954
Dr. Eric L. Sievers M.D. Chief Medical Officer 1964
Mr. Christian Vasquez VP of Fin., Corp. Controller & Sec. 1975
Mr. Philippe Martin Chief Clinical Devel. & Operations 1976
Lisa M. Pelton Accounting Mang. NA
Ms. Susie Melody Sr. VP of HR NA
Dr. Cathy Chang Ph.D. Sr. VP of R&D NA
Ms. Monica Sullivan Sr. VP of Intellectual Property & Contracts NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions